argenx Presents Broad VYVGART Data at AANEM/MGFA, Including Ocular MG and Seronegative MG Results
ARGX sits 47% above its 52-week low of $661.85.
Summary
argenx presented new data at AANEM/MGFA showing VYVGART's benefit in ocular MG and seronegative MG, real-world evidence favoring earlier treatment, and long-term CIDP safety/efficacy, plus pipeline updates for empasiprubart and adimanebart.
Key Events · Product Development and Regulatory · ARGX
-
Ocular MG Data Deepens
Phase 3 ADAPT OCULUS data show VYVGART's ocular MG benefit deepens with additional cycles: MGII ocular scores improved from -4.5 to -6.8 points in AChR-Ab-positive patients and from -2.7 to -4.5 in triple-seronegative patients after two additional cycles.
-
Seronegative MG Efficacy Sustained
One-year ADAPT SERON results show sustained efficacy in anti-AChR antibody-negative gMG, with mean MG-ADL improvements of approximately 5 points maintained through Week 52.
-
Earlier Treatment Shows Greater Benefit
Real-world analysis of >1,100 U.S. MG patients found those treated with VYVGART within a year of diagnosis had a mean MG-ADL reduction of 4.7 points over three months versus 3.5 points for those treated >3 years after diagnosis, with 50% reaching minimal symptom expression.
-
CIDP Long-Term Data Reinforce Profile
ADHERE/ADHERE+ interim analysis with >5 years follow-up shows consistent safety; approximately 40% of responding CIDP participants reached an INCAT score of 0 or 1, indicating independence in most daily activities.
Analysis · ARGX · Life Sciences
argenx unveiled a large batch of new clinical and real-world data at the AANEM and MGFA scientific sessions, headlined by Phase 3 ADAPT OCULUS results showing VYVGART's benefit deepens with additional cycles in ocular MG, and one-year ADAPT SERON data demonstrating sustained efficacy in anti-AChR antibody-negative generalized MG. The real-world analysis of over 1,100 U.S. patients showing greater benefit with earlier treatment initiation supports a commercial narrative of expanding VYVGART use earlier in the treatment paradigm. Long-term CIDP data extending beyond five years and Phase 4 switch data supporting a one-week IVIg transition further strengthen the franchise. Pipeline readouts for empasiprubart in MMN and adimanebart in DOK7-CMS add optionality. This is a data-rich disclosure that could support label expansion and commercial growth, though it is conference data rather than a regulatory decision.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29.3% of the 1512 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARGX was trading at $970.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.1B. The 52-week trading range was $661.85 to $1,072.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.